Company ProfilePremium

OncoSil Medical Limited

Company Profile Analysis

Ticker: OSL.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
OncoSil Medical Limited - Company showcase

Year Founded & Workforce

2005

4,960,000 Employees

OncoSil Medical Limited logo

OncoSil Medical Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

OncoSil Medical Limited Overview

OncoSil Medical is a single-product, early-commercial-stage Australian medical device company in interventional oncology. Its OncoSil™ device is a Class III, single-use brachytherapy implant. It places phosphorus-32 (³²P) microparticles directly into pancreatic tumours under endoscopic ultrasound (EUS) guidance, alongside chemotherapy. The device has CE Mark/MDR certification for unresectable locally advanced pancreatic cancer (LAPC) with gemcitabine-based chemotherapy and is approved in more than 30 countries. Australian TGA approval followed in May 2026, and US FDA Humanitarian Device Exemption (HDE) approval for distal cholangiocarcinoma (dCCA) followed on 17 August 2026. Revenue is still small (A$1.68m in FY2026, up 43.9%). The company remains loss-making (FY2026 net loss A$10.86m) and depends on equity markets, as reflected in the going-concern material uncertainty. The investment case turns on three things: converting a growing clinical evidence base (TRIPP-FFX, OSPREY, PANCOSIL, and a G-BA trial in Germany) into reimbursed, routine use; extending the label to FOLFIRINOX and percutaneous delivery; and executing launches in the US and Australia in 1H CY2027.


Company's own description (FY2026 Annual Report, Directors' Report). The Group describes its principal activities as "the development and commercialisation of its lead product candidate, the OncoSil™ localised radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma." In the Review of Operations it describes itself as "an ASX-listed medical device company which has developed a breakthrough implantable radiation (brachytherapy) device for patients with pancreatic cancer." ASX announcement boilerplate from 2026 calls it "a global medical device company focused on Interventional Oncology."

What the product does. OncoSil™ consists of ³²P microparticles suspended in a specially formulated diluent. A gastroenterologist or endoscopist implants it into the pancreatic tumour using a fine needle under EUS guidance, usually after induction chemotherapy. ³²P emits pure beta radiation over a very short path length. This delivers a high local dose while sparing nearby organs. The company points to a June 2026 peer-reviewed publication that verified strong localisation of the radiation in the pancreas.

Clinical rationale. About a third of pancreatic cancers present as locally advanced, unresectable disease. In these patients, encasement of blood vessels prevents surgery and systemic chemotherapy alone gives limited local control. OncoSil aims to:

  • improve local disease control;

  • downstage selected patients to surgical resection; and

  • extend survival.

All of this is intended to work without the multi-session hospital visits that external radiotherapy such as SBRT requires.

Business model and revenue model.

Product sales, 100%: All revenue (A$1,684,978 in FY2026) comes from sales of the OncoSil device. Revenue is recognised at a point in time, when the procedure has been performed and the device used on the patient (FY2026 Annual Report, Note 5). There is no service, subscription or licensing revenue.

Channel mix: Hybrid model. The company sells directly in core European markets through OncoSil Medical Europe GmbH (Germany, Spain, Italy, the UK, Austria, Portugal and others). It uses exclusive distributors in peripheral markets: EDH Nuclear in Türkiye, Al Zahrawi Medical Supplies in the GCC including Saudi Arabia, Femto Trade in Egypt and CardiRad in the Nordics.

Other income: The Australian R&D Tax Incentive (RDTI) is a material non-revenue inflow: A$3.40m recognised in FY2026 and A$1.84m cash received.

Value chain position. OncoSil is the regulatory manufacturer and brand owner. Upstream, it buys microparticle precursors and radio-activation services. Historically it relied on contract nuclear manufacturing in Europe. It is now moving to a proprietary process in Sydney with Cyclotek, after a manufacturing validation programme of more than 50 validation doses and about A$2.1m of specialised equipment (ASX, 13 Jul 2026). Downstream, it sells to hospitals, which recover costs through national or regional reimbursement schemes. Examples are Germany's NUB innovation funding, Italian regional procurement and Saudi reimbursement for nationals.

Customer types. Public and private hospitals, mainly university or tertiary oncology centres with interventional endoscopy (EUS) capability. The FY2026 Annual Report notes no customer exceeded 10% of revenue. The company cites 28 commercially active treatment centres at Q3 FY2026, up 56% year on year (Quartr summary of the Q3 FY2026 quarterly).

End-markets served. Oncology, specifically:

  • unresectable LAPC (CE Mark, TGA);

  • unresectable, non-metastatic dCCA (US HDE).

Pipeline indications are FOLFIRINOX combination (CE Mark extension submission planned for 2H CY2026), percutaneous CT-guided delivery by interventional radiologists (submission planned for 2H CY2026) and repeat treatment (PULSE study).

Independent characterisation. OncoSil is best understood as a pre-scale, single-asset medtech moving from "approved but under-adopted" to "commercially reimbursed." Unit economics are still negative. Cost of goods (A$2.36m) exceeded revenue (A$1.68m) in FY2026, because of low volumes, contract manufacturing costs and radioisotope logistics. The Sydney manufacturing transition is therefore central to any path to positive gross margin. The model resembles the early history of Sirtex Medical (SIR-Spheres), whose former executives now lead OncoSil: CEO Nigel Lange was Sirtex's Group Chief Commercial Officer, and Chair Thomas Duthy ran Sirtex's corporate development and investor relations. The playbook follows that precedent: build Key Opinion Leader (KOL) evidence, win reimbursement in Germany and expand centre by centre.

Strategy

Stated strategy themes (FY2026 Chairman's letter and CEO's report).

  1. "Clinical momentum converting to commercial outcomes." Use TRIPP-FFX, OSPREY, PANCOSIL and independent data (Royal Adelaide SBRT comparison) to build physician confidence.

  2. "Germany: The pivotal market." The G-BA-sponsored study (starting 2H CY2026) could unlock reimbursement across Germany's public hospital system. Germany has about 20,000 new pancreatic cancer cases a year, with 2,000–3,000 addressable patients, and its decisions are referenced by other European states.

  3. Label expansion. FOLFIRINOX combination and percutaneous delivery to broaden eligible patients and the specialist user base.

  4. New markets. US launch (HDE, dCCA) and Australian launch (TGA) in 1H CY2027; Saudi Arabia via Al Zahrawi.

  5. Manufacturing sovereignty and margin. Complete the Macquarie Park/Cyclotek facility to cut COGS, improve gross margin and add supply resilience.

  6. Capital discipline. A$3.4–3.9m of annualised cost savings from FY2027; R&D outflows to decline from Q2 FY2027; equity-based pay for the board and CEO.

Initiatives in the last 24 months

Guidance and targets.

  • Management previously targeted cash-flow breakeven by H2 CY2026 (May 2025 raise announcement). This has not been achieved: FY2026 operating cash outflow was A$10.5m.

  • Current guidance is qualitative: US and Australian launches in 1H CY2027, regulatory filings in 2H CY2026, G-BA trial commencement, manufacturing start-up, and declining R&D outflows.

  • No quantitative revenue or earnings guidance has been issued.

Products & Services

The company has one commercial product. Each approved indication, delivery method and development extension is catalogued separately below.

The device holds breakthrough device designation in the EU, UK and US (company descriptions, 2025).

Product Portfolio

OfferingDescriptionKey specifications / capabilitiesTarget customerStatus / yearPricing

OncoSil™ device — LAPC with gemcitabine-based chemotherapy (EU/UK)

Single-use brachytherapy device: ³²P microparticles in diluent, implanted intratumourally under EUS guidance

Pure beta emitter; highly localised dose (localisation verified in a June 2026 publication). One-time procedure after induction chemotherapy. Supplied sterile, single patient.

EUS endoscopists / interventional GI at tertiary oncology centres

CE Mark (circa 2020); EU MDR certification Jan 2025 (BSI); UKCA renewed without post-market restrictions (Jan 2025)

Per-dose hospital price not disclosed. Germany: hospital-negotiated NUB fees.

OncoSil™ — Australia (TGA)

Same device, ARTG-listed

For unresectable LAPC with gemcitabine-based chemotherapy

Australian public/private hospitals (about 4,350 new pancreatic cancer cases a year)

Approved 20 May 2026; launch targeted 1H CY2027

—

OncoSil™ — USA (FDA HDE), dCCA

Humanitarian Device Exemption

Unresectable (locally advanced and/or unfit for surgery), non-metastatic dCCA, as an adjunct to systemic therapy

US specialist hepatobiliary/GI oncology centres; about 1,000 eligible patients a year

Approved 17 Aug 2026; launch targeted 1H CY2027

Company cites an A$80m US TAM, implying about A$80k per treatment (derived). HDE pricing limits may apply.

OncoSil™ — Middle East / other CE-recognising markets

Distributor-led sales

Same specification

Hospitals via exclusive distributors

Approved in more than 30 countries, including Türkiye, Israel, Hong Kong, Singapore, Malaysia, New Zealand and Switzerland. Saudi SFDA approval Jul 2026, with full reimbursement for Saudi nationals.

Distributor transfer pricing not disclosed

Percutaneous (CT-guided) delivery — pipeline

Alternative to EUS implantation, delivered by interventional radiologists

Supported by PANCOSIL (20 patients, Amsterdam UMC); safe and feasible (CIRSE 2025)

Interventional radiology / interventional oncology

Regulatory submission targeted 2H CY2026

—

FOLFIRINOX combination label — pipeline

Label extension to today's standard of care

TRIPP-FFX: 82.2% local disease control rate at 16 weeks (95% CI 68–92%); median OS 18.3 months with OncoSil + FOLFIRINOX

Medical oncologists, Europe

CE Mark extension submission targeted 2H CY2026

—

Repeat treatment — pipeline

Second OncoSil implantation in non-progressive LAPC after induction chemotherapy

PULSE Phase II: 120 patients, 5 centres, 1:1 randomised; devices supplied in kind

Academic PALACROS centres

Study start under PALACROS (announced 2 Jul 2026)

—

US pancreatic cancer indication — long-term

Premarket Approval (PMA) route

A "Global Pivotal Clinical Study" to support a future US premarket application for pancreatic cancer

US market

Planned; no timeline disclosed

—

Support services

Physician training, proctoring, KOL advisory boards (e.g., London Advisory Board, Jan 2025), OSPREY registry

Not separately monetised

Treating centres

Ongoing

Bundled

“—” = not publicly disclosed.

Financial Narrative

Income statement: notes and sources

Sources: FY2026 AR income statement and 5-year table; FY2025 4E. FY2022–23 cost of revenue is from Kalkine (secondary). Operating loss (derived) = pre-tax loss + finance costs − interest revenue. EBITDA (derived) = operating loss + depreciation (FY2026 A$59.5k; FY2025 A$35.7k). No amortisation; no capitalised development.

Margins and growth

Revenue CAGR: FY2022–FY2026 (4 years) about 64.2% (derived: 1,685.0 / 231.8). FY2024–FY2026 (2 years) about 80.6%.

Commentary. Revenue has compounded quickly from a tiny base. The inflection in FY2025 (+126.6%) followed MDR certification in January 2025 and German NUB eligibility. Growth continued in FY2026 (+43.9%; unit sales +53%) with new launches in Portugal, Germany and the UK. Gross margin is still negative but improving sharply, from −92.5% to −39.9%. This reflects fixed manufacturing and isotope logistics costs being spread over more doses. Cost of sales rose only 4.6% while revenue rose 43.9%. The FY2026 loss narrowed 28.1% to A$10.86m. The main driver was a jump in recognised RDTI income (A$3.40m vs A$0.36m), together with lower consulting, legal and administrative costs (−A$1.59m combined). R&D expense rose 30% to A$5.47m as TRIPP-FFX and PANCOSIL closed out. Excluding RDTI, the underlying operating loss was about A$14.4m in FY2026 vs A$15.6m in FY2025 (derived). Underlying cost discipline is therefore improving more slowly than the headline suggests. Management has identified A$3.4–3.9m of annualised savings from FY2027 and expects R&D cash outflows to fall from Q2 FY2027.

Balance sheet

Sources: FY2026 AR (FY2025–26 and the 1 Jul 2024 equity balance); Kalkine and moomoo (secondary) for FY2022–24 cash, receivables, PP&E, net debt and liabilities. FY2023 and FY2024 total assets are derived as equity/NTA plus liabilities (approximate).

Commentary. There is no financial debt. The only debt-like items are small lease liabilities (A$14.8k). The balance sheet consists of cash plus receivables, and the receivables likely include accrued RDTI (FY2026 RDTI recognised A$3.40m vs cash received A$1.84m). Equity of A$5.0m against accumulated losses of A$117.3m shows the scale of capital consumed since inception, about A$105m of issued capital. Payables rose to A$5.20m, including A$679k owed to Cyclotek. With current assets of A$9.38m, liquidity is adequate but tight. Pro forma cash after the September 2026 raise is A$12.1m (company estimate).

Cash flow

Sources: FY2026 AR cash flow statement; InvestSMART (secondary) for FY2024 operating and financing cash flows.

Commentary. Customer receipts rose 179% to A$2.1m. This exceeded recognised revenue, implying collection of prior-period receivables. Cash burn (operating cash flow) improved 13% to A$10.5m. Reported capex is negligible because the manufacturing equipment (about A$2.1m) appears to be funded through supplier payables and accruals: PP&E rose by A$558k while the cash outflow was only A$1.5k. Expect higher cash capex as those payables are settled. FY2026 average quarterly burn was about A$2.6m. The Q4 FY2026 net operating outflow was A$2.6m (Appendix 4C, 30 Jul 2026), which implies roughly 4–5 quarters of runway on pro forma cash of A$12.1m before cost savings and US/Australian launch costs.

Ratios

Net debt/EBITDA is shown as a positive ratio because both net debt (net cash) and EBITDA are negative; it is not economically meaningful. ROIC and interest coverage are not meaningful (no invested debt capital; EBIT is negative). The cash conversion cycle is not meaningful because receivables are dominated by RDTI and inventory is negligible (A$5.6k in FY2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Segment revenue OncoSil device (AUD K)

516.61,170.81,685.0

YoY revenue growth (%)

40.5126.643.9

Contribution to total revenue (%)

100100100

Segment pre-tax loss (AUD K)

-11,913.6-15,099.8-10,860.1

Segment net margin (%)

-2,306.1-1,289.7-644.5

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Sales revenue (AUD K)

231.8367.7516.61,170.81,685.0

Total revenue and other income incl. RDTI and interest (AUD K)

1,073.51,530.01,631.91,626.25,228.7

Cost of sales (AUD K)

9701,590—2,253.62,357.3

Gross profit (AUD K)

-738-1,222—-1,082.8-672.3

R&D expense (AUD K)

———4,210.95,472.3

Employee benefits expense (AUD K)

———4,896.74,958.2

RDTI other income (AUD K)

———364.53,404.1

Operating loss incl. RDTI (AUD K) (derived)

———-15,189.8-10,982.9

EBITDA (AUD K) (derived)

———-15,154.1-10,923.4

Pre-tax loss (AUD K)

-10,726.7-11,342.9-11,913.6-15,099.8-10,860.1

Net loss (AUD K)

-10,726.7-11,342.9-11,913.6-15,099.8-10,860.1

Basic EPS (A$ cents, post-consolidation)

-529.21-401.66-215.60-138.17-47.95

Diluted EPS (A$ cents)

-529.21-401.66-215.60-138.17-47.95

Dividends per share (AUD)

00000

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue growth YoY (%)

8.858.640.5126.643.9

Gross margin (%)

-318-332—-92.5-39.9

Operating margin (%) (derived)

———-1,297.4-651.8

EBITDA margin (%) (derived)

———-1,294.3-648.3

Net margin (%)

-4,627-3,085-2,306-1,289.7-644.5

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Cash & equivalents (AUD K)

11,2809,3904,501.45,109.76,475.9

Trade & other receivables (AUD K)

9101,2901,3501,204.52,443.7

Total current assets (AUD K)

———6,723.99,381.3

Plant & equipment (AUD K)

324.9239.3112.8359.0916.7

Total assets (AUD K)

—11,4706,5067,148.110,311.3

Trade & other payables (AUD K)

———3,855.65,196.2

Total debt incl. leases (AUD K)

———69.914.8

Short-term debt / leases (AUD K)

———53.714.8

Long-term debt / leases (AUD K)

———16.20

Net debt (negative = net cash) (AUD K)

-10,976-9,223-4,431-5,039.8-6,461.1

Total liabilities (AUD K)

1,9101,5901,7704,044.65,314.9

Total equity (AUD K)

——4,736.43,103.54,996.4

Net tangible assets (AUD K)

11,1609,880—3,108.14,997.9

Goodwill & intangibles (AUD K)

00000

Working capital (AUD K) (derived)

———2,701.74,074.0

Accumulated losses (AUD K)

——-92,781.2-107,457.8-117,322.8

Issued capital (AUD K)

——90,094.096,425.1105,455.7

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Receipts from customers (AUD K)

———758.52,115.0

RDTI cash received (AUD K)

———1,050.91,840.1

Operating cash flow (AUD K)

——-11,130-12,062.3-10,472.4

Capex PP&E (AUD K)

———-15.0-1.5

Free cash flow (AUD K) (derived)

———-12,077.3-10,473.9

Equity issued net incl. options (AUD K)

——6,00012,780.611,916.9

Net financing cash flow (AUD K)

——6,00012,726.711,861.7

Dividends paid (AUD K)

00000

Buybacks (AUD K)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2025FY2026

ROE (%) (derived, avg equity)

-385.2-268.2

ROA (%) (derived, avg assets)

-221.2-124.4

Current ratio (x)

1.671.77

Debt / equity (x)

0.020.00

Net debt / EBITDA (x)

0.330.59

Asset turnover (x) (derived)

0.170.19

Revenue by Region

RegionFY2024FY2025FY2026

Australia revenue (AUD K)

—15.091.4

Europe revenue (AUD K)

—869.61,404.5

Middle East and United Kingdom revenue (AUD K)

—286.2189.1

Total revenue (AUD K)

516.61,170.81,685.0

Revenue by Region (%)

Region (%)FY2026 YoY growth (%)FY2026 share of revenue (%)

Australia

509.15.4

Europe

61.583.4

Middle East and United Kingdom

-33.911.2

Share Price and Share Count (m)

MetricFY2022FY2023FY2024FY2025FY2026

Share price at 30 June (AUD)

13.004.801.601.200.71

Shares on issue at 30 June (m)

———14.2230.89

Market cap at 30 June (AUD Mn, InvestSMART)

——131722

Valuation Multiples

MultipleOncoSilComment

Market cap

~A$38m

~36.7m shares × ~A$1.05

Enterprise value

~A$26m

Less pro forma cash of A$12.1m; no debt

EV / Sales (FY2026)

~15.7x

On A$1.685m revenue

P/E

n/m

Loss-making

EV/EBITDA

n/m

Negative EBITDA

P/B (reported FY2026 equity A$5.0m)

~7.6x

~3.6x on pro forma equity of about A$10.6m (derived)

Share Price & Returns

DateRaisePrice (A$, post-consolidation basis)

Oct–Nov 2024

Up to A$8m (placement + SPP)

~A$2.80 equivalent (pre-consolidation ~A$0.007)

May–Jul 2025

A$8.7m (placement + SPP)

A$1.20 equivalent (A$0.003 × 400)

Jul 2025

A$3.5m placement

A$1.20

Feb–Mar 2026

A$8.0m (placement + entitlement offer)

A$0.68

Sep 2026

A$4.0m placement + A$1.6m options

A$1.00 / A$0.90

Analyst Conclusions

Management guidance (FY2026 AR and Sep 2026 announcement)

  • US commercial launch (HDE, dCCA) and Australian launch (TGA, LAPC) in 1H CY2027.

  • Two European regulatory filings in 1H FY2027: FOLFIRINOX CE Mark extension and percutaneous delivery.

  • G-BA-funded trial in Germany to commence (2H CY2026).

  • Start of commercial manufacturing at the OncoSil/Cyclotek facility in Sydney, subject to approval.

  • Annualised cost savings of A$3.4–3.9m from FY2027; R&D cash outflows declining from Q2 FY2027.

  • No quantitative revenue, margin or breakeven guidance is current. The earlier "cash-flow breakeven by H2 CY2026" target is effectively superseded.

Consensus growth expectations. Not publicly available. Recent run-rates point to continued 40–60% revenue growth in Europe (FY2026 +43.9%; Q3 FY2026 +49%). US and Australian contributions are unlikely to be material before 2H FY2027.

Bull case

  1. Dual approvals de-risk the platform. FDA HDE (a rare achievement for an ASX device company) and TGA approval open two new markets: an A$80m US dCCA TAM plus the Australian home market. The HDE also creates a US clinical base for a future pancreatic PMA.

  2. German reimbursement could be the inflection. A positive G-BA pathway would unlock 2,000–3,000 addressable patients and set a reference for other EU systems. Even 10% penetration would be a multiple of current volumes.

  3. Operating leverage is visible. COGS was flat while revenue grew 44%. Sydney manufacturing, A$3.4–3.9m of cost savings and falling trial spend could narrow cash burn sharply, while the registry and investigator-led evidence base keeps growing.

Bear case

  1. Funding treadmill. Pro forma cash of A$12.1m against roughly A$10m+ annual burn, plus launch costs in two new countries, means more dilution is likely in 2027. There are 27m options outstanding and the going-concern uncertainty remains.

  2. Commercial scale remains unproven. After years on the market in Europe, revenue is A$1.7m with negative gross margin. HDE commercial constraints (patient cap, potential profit limits, IRB requirements) may make the US more strategic than lucrative near term.

  3. Evidence gap. No randomised, OS-powered superiority trial exists. TRIPP-FFX was non-comparative, and registry or retrospective data may not secure guideline inclusion or HTA approval, while alternatives (SBRT, TTFields, EUS-RFA) keep advancing.

Key catalysts and monitorables (next 12 months)

Concluding analyst verdict

OncoSil Medical enters FY2027 in the strongest strategic position of its 21-year listed history, and with one of its weakest-looking income statements relative to that position. Regulatory risk, which dominated the equity story for a decade, has largely been retired. The company has an MDR certificate, TGA inclusion, an FDA HDE and Saudi approval. The device is also accumulating credible real-world survival data from independent European and Australian investigators. Those are hard-won assets for a company with a market capitalisation of about A$38m.

What remains is commercial and financial execution risk, and that risk is substantial. FY2026 revenue of A$1.68m against cost of sales of A$2.36m shows the business does not yet earn a positive gross margin. Operating cash burn of A$10.5m against pro forma cash of A$12.1m implies another equity raise within roughly 12 months unless burn falls quickly. The auditor's going-concern emphasis is warranted. The earlier breakeven target for H2 CY2026 was missed, which should temper reliance on management timetables.

The investment debate therefore comes down to three measurable variables:

  • the gross-margin step-change from Sydney manufacturing;

  • the pace of German adoption ahead of and through the G-BA trial; and

  • the real economics of the US HDE launch, including any profit constraints under the HDE framework.

The September 2026 placement at a premium, funded by the three largest institutional holders, is a meaningful signal of informed conviction. Even so, the dilution history and a 27m-option overhang cap per-share upside in the near term.

Verdict: a high-risk, catalyst-rich micro-cap. The risk/reward is asymmetric if German reimbursement and margin improvement arrive together in FY2027. It is unattractive if commercial volumes stall and funding must be raised at a discount. Base-case stance: speculative/neutral, pending evidence of positive gross margin and quarterly receipts above A$1m.


Sources: OncoSil Medical FY2026 Appendix 4E & Annual Report (28 Aug 2026); FY2025 Appendix 4E (Aug 2025); FY2023 Annual Report (31 Aug 2023); ASX announcements of 30 Jan 2025, 25 Feb 2025, 29 Apr 2025, 26 May 2025, 2 Jul 2026, 13 Jul 2026, 20 Jul 2026, 30 Jul 2026, 17 Aug 2026, 7 Sep 2026 and 8 Sep 2026; prospectus of 3 Feb 2026; ClinicalTrials.gov NCT05466799; pSivida SEC filings (2005–2008). Secondary sources: InvestSMART/Morningstar, Kalkine, moomoo, Stoxray, TipRanks, Biotech Dispatch, Biotech Daily, Medical Device Network, BioSpectrum Asia, Quartr, Stockhead, roic.ai. Derived figures are analyst calculations from reported line items. Competitor figures are approximate and should be verified against those companies' filings.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackgroundEducationCommittees

Dr Thomas Duthy

Non-Executive Chairman

NED 11 Jul 2025; Chair 1 Oct 2025

22+ years in financial markets and healthcare corporate development. Founder of Nemean Group. Former Head of Corporate Development & IR at Sirtex Medical (A$1.9bn sale to China Grand Pharma/CDH). Advised on the Ellex/Lumibird, Limeade/WebMD and Pivotal Systems transactions. Recent former directorships: Arovella, Neurotech, Neurizon, Invex.

PhD (University of Adelaide), MBA (Deakin)

NRC, ARC (member)

Nigel Lange

CEO & Managing Director

Joined May 2020; CEO agreement from 21 Jan 2021

40+ years in medical devices. At Sirtex from 2003: CEO Europe (300+ centres), Group CCO from 2017, interim Group CEO and interim CEO APAC.

BA, B.Comm

NRC, ARC (member)

Lel Smits

Non-Executive Director

Mid-Jan 2025

Managing Director of The Stock Network (investor media). Australian Shareholders' Association director 2021–2026. Former broadcast finance journalist.

AICD graduate; Dip. IR (AIRA); MA Journalism (UTS); BMedia, BA (Adelaide)

NRC, ARC (member)

Douglas Cubbin

Former Chairman

Resigned as Chair 1 Oct 2025; retired 19 Nov 2025

Also NED of Cyclotek (related party)

——

Dr Gabriel Liberatore

Former NED

Resigned 11 Jul 2025 (personal reasons)

———

Executive Leadership Team

NameTitleTenureNotes

Nigel Lange

CEO & MD

CEO since Jan 2021

Base salary €260,000 plus about €25,000 in benefits. STI up to 35%, LTI up to 35%. Six months' notice.

Shelley Steyn

CFO

Since 5 May 2025

Base A$270,000 plus super. STI up to 25%. 12 weeks' notice.

Dr Ralph Peters

Chief Medical Officer (per Kalkine)

—

Secondary source only

David Turner

Head of Medical Affairs (per Kalkine)

—

Secondary source only

Rachel Duggan

EMEA Sales Director

Since Oct 2024

ASX announcement, 29 Oct 2024

Directors' Remuneration

PersonCash salary/feesCash bonusNon-monetarySuperLSLOptionsSharesPerf. rightsTotal

Dr Thomas Duthy (Chair)

66,300000086,71245,2000198,212

Douglas Cubbin

30,085003,61003,9520037,647

Lel Smits

18,333002,20002,00033,434055,967

Gabriel Liberatore

4,129004960184004,809

Nigel Lange (CEO)

428,31946,92947,7110053,1235,325156,406737,813

Shelley Steyn (CFO)

270,00057,400030,00066941800358,487

Total KMP

817,166104,32947,71136,306669146,38983,959156,4061,392,935

Major Shareholders

HolderStakeSource / note

Pengana Capital Group / Pengana High Conviction Equities Fund

Substantial (>5%); among the three largest holders

Cornerstone in the May 2025, Feb 2026 and Sep 2026 raises. Exact % not publicly verified.

Regal Partners / Regal Funds Management

Substantial; among the three largest

Cornerstone Feb 2026; Sep 2026 placement

Australian Ethical Investment

Among the three largest

Sep 2026 placement

Washington H. Soul Pattinson (SOL)

Lodged a "change in substantial holding" on 18 Jun 2025

—

Directors & KMP combined

313,000 shares at 30 Jun 2026, about 1.0% of 30.9m shares

FY2026 AR. Plus 644,121 options and 234,925 performance rights.

Competitive Landscape

Key Competitors

CompetitorOfferingSegment overlapRelative positioning vs OncoSil

Elekta (Sweden)

Linear accelerators, Unity MR-Linac (SBRT/MR-guided RT)

External radiotherapy for LAPC

Entrenched installed base; non-invasive but needs 5+ fractions. OncoSil cites superior OS vs SBRT in the Adelaide data.

Siemens Healthineers / Varian

TrueBeam/Halcyon linacs, SBRT

External RT

Dominant RT vendor; same dynamic as Elekta

Accuray (US)

CyberKnife SBRT

External RT

Niche SBRT

AngioDynamics (US)

NanoKnife irreversible electroporation (IRE)

Local ablation of LAPC

Open or laparoscopic surgical procedure; US-focused; mixed evidence

Novocure (US/Jersey)

Tumour Treating Fields, LAPC (PANOVA-3 trial)

Local-regional LAPC therapy

Well-funded; wearable, non-invasive. Regulatory status in pancreatic cancer to be verified.

Alpha Tau Medical (Israel)

Alpha DaRT (radium-224 intratumoural alpha emitter)

Intratumoural brachytherapy, pancreas trials

Closest technology analogue; pre-commercial in pancreas

Perspective Therapeutics / Isoray (US)

Cs-131 seed brachytherapy

Brachytherapy

Focus is other tumour types

Sirtex Medical (CDH/China Grand Pharma)

SIR-Spheres Y-90

Liver-directed radioembolisation; potential cholangiocarcinoma overlap

Global commercial infrastructure; comparable business model

Boston Scientific

TheraSphere Y-90; EUS-RFA accessories

Liver/biliary radiotherapy; EUS ecosystem

Scale player; could be competitor or acquirer (speculative)

Taewoong Medical / STARmed

EUS-guided radiofrequency ablation (EUS-RFA)

EUS-delivered local ablation of pancreatic tumours

Low-cost, same EUS channel; emerging data

Ipsen

Onivyde (NALIRIFOX)

Systemic therapy

Complementary or competing for the treatment budget

AstraZeneca / Merck

Durvalumab / pembrolizumab + gem/cis in biliary tract cancer

Systemic dCCA standard of care

OncoSil's HDE is "adjunct to systemic therapy", so complementary

Peer Comparison FY2026

MetricOncoSil (FY2026)Novocure (CY2024)AngioDynamics (FY2025, May YE)

Revenue

A$1.7m

~US$605m

~US$290m

Revenue growth

+43.9%

~+19%

low single digit

Gross margin

−39.9%

~75–80%

~50–55%

Net margin

−644.5%

negative

negative

R&D intensity (% of revenue)

~325%

~35%

~10%

Recent Developments

--

Company Snapshot

4,960,000

Employees

2005

Founded

Australia

Headquarters

SWOT Analysis

Strengths

  • Multi-jurisdiction Class III approvals. CE/MDR (Jan 2025), TGA (May 2026), FDA HDE (Aug 2026) and SFDA (Jul 2026); approved in more than 30 countries.
  • Encouraging survival data. OSPREY real-world median OS of 20.6–22.0 months; Royal Adelaide 22 vs 14 months vs SBRT; TRIPP-FFX LDCR 82.2% with median OS 18.3 months.
  • Accelerating commercial traction. FY2026 revenue +43.9%, units +53%, customer receipts +179%; 28 active centres at Q3 FY2026 (+56%); 100th Spanish patient.
  • Improving unit economics. Gross margin improved from −92.5% to −39.9% as cost of sales rose only 4.6%.
  • Committed institutional register. The three largest holders funded A$5.6m at a 9.9% premium (Sep 2026) and exercised options nine months early.
  • Management with relevant precedent. CEO built Sirtex Europe to 300+ centres; Chair was central to the A$1.9bn Sirtex sale.
  • No debt. Lease liabilities of only A$14.8k.

Weaknesses

  • Going-concern material uncertainty in both FY2025 and FY2026 audit opinions.
  • Negative gross profit (−A$0.67m in FY2026); COGS exceeds revenue.
  • Persistent losses and burn. Net loss A$10.86m; operating cash outflow A$10.47m against A$6.48m of year-end cash.
  • Missed breakeven target. The May 2025 target of cash-flow breakeven by H2 CY2026 has not been met.
  • Single product, single technology. 100% of revenue from one device.
  • Thin governance. Three-person board with the CEO on the audit and remuneration committees; NRC did not meet in FY2026; related-party links (Cyclotek, The Capital Network).
  • Heavy dilution history. Shares on issue more than doubled in FY2026 (14.2m to 30.9m); 27.2m options outstanding; 1:400 consolidation in 2025.

Opportunities

  • US entry via HDE. About 1,000 patients a year and an A$80m TAM per the company; a platform for a future PMA in pancreatic cancer.
  • German national reimbursement through the G-BA trial: 2,000–3,000 addressable patients, plus reference effects across Europe.
  • FOLFIRINOX label extension (2H CY2026 filing), aligning with the current standard of care in fit patients.
  • Percutaneous delivery opens the interventional radiology specialty (PANCOSIL).
  • Australian home-market launch (4,353 cases a year) with domestic manufacturing.
  • Low-cost evidence generation through PALACROS/PULSE (devices in kind; about A$9m saving claimed).
  • Margin uplift from Sydney manufacturing (about A$2.1m of equipment installed).

Threats

  • Funding risk. Pro forma cash of A$12.1m against roughly A$10m+ annual burn plus launch costs; further dilution is likely.
  • HDE commercial constraints. HDE devices face regulatory limits, including on profit.
  • Evidence risk. Non-randomised and non-comparative datasets may not satisfy health technology assessment or guideline bodies.
  • Competitive modalities. Elekta/Varian SBRT, Novocure TTFields, EUS-RFA and Alpha DaRT.
  • Manufacturing and isotope supply. Scale-up "substantially underway but not complete" (FY2026 risk section).
  • Licensor milestone. psiMedica payment triggers at US$5m cumulative sales (57.5% achieved).
  • Key-person dependence on a small executive team.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
29 Apr 2025Q3 FY2025 quarterly: record dose sales; nine-month revenue exceeds all of FY2024Commercial inflection
7 May 2025Royal Adelaide data: OncoSil OS 22 months vs SBRT 14 months (DDW 2025)Independent comparative evidence
26 May 2025A$8.7m raise announced (at A$0.003 pre-consolidation); targets cash-flow breakeven by H2 CY2026Funding; breakeven target later missed
29 May / 6 Jun 2025EGM approves 1:400 consolidation; completedCapital structure reset
Jun 2025Substantial holder changes lodged (Pengana; Soul Patts)Register rotation
4 Jul 2025PANCOSIL 100% recruited (20th patient)Pipeline milestone; CEO LTI Tranche 1
11 Jul 2025A$2m SPP completed (about A$4.5m applications); Duthy joins board; Liberatore resignsFunding; governance
14 Jul 2025A$3.5m placement at A$1.20 with OSLOD optionsFunding
23 Jul 2025TRIPP-FFX fully recruitedPipeline
29 Jul 2025Q4 FY2025 quarterly; cash A$5.1mLiquidity
Aug 2025FY2025 results: revenue +126.6% to A$1.17m; loss A$15.1m; going-concern uncertaintyFinancial
18 Sep 2025PANCOSIL positive preliminary results (CIRSE 2025)Percutaneous route validated
Sep 2025Pancreatic Cancer Europe cooperationAdvocacy
1 Oct 2025Duthy appointed ChairGovernance
2–3 Oct 2025First patient in Portugal (IPO Porto)New market
15–16 Oct 2025First patient in Germany (Augsburg)Key market entry
30 Oct 2025Q1 FY2026: cash A$5.9m; receipts A$0.6m; RDTI refund expected A$1.8mLiquidity
3 Nov / 19 Nov 2025Cubbin announces retirement; AGM (remuneration report 98.78% for)Governance
3 Dec 2025OSPREY interim: median OS 20.6 / 22.0 monthsReal-world evidence
9–10 Dec 2025First UK commercial patient (Southampton)New market
17 Dec 2025First hot production test run in SydneyManufacturing
30 Jan 2026Q2 FY2026 quarterly; cash A$2.9m at 31 Dec 2025Low cash prompted the raise
3 Feb 2026A$8m raise (A$6m placement + A$2m underwritten entitlement offer at A$0.68)Funding at a discount
12 Feb 2026CEO to take 10% of salary in sharesAlignment
24 Feb 2026H1 FY2026 resultsFinancial
12–17 Mar 2026EGM; placement Tranche 2 and entitlement offer completedFunding
28 Apr 2026Q3 FY2026: dose sales +60%, revenue +49%, 28 active centres (+56%); cash A$9.3mCommercial traction
15 May 2026OSPREY interim presented at ESGE Days 2026 (oral)KOL visibility
20 May 2026TGA approval (LAPC + gemcitabine)Home-market access
22 May 2026New clinical evidence presented at ASCOVisibility
4 Jun 2026Trading haltPending material news
9 Jun 2026TRIPP-FFX meets co-primary endpoints; FDA HDE at final reviewMajor re-rating (A$0.435 to about A$1.50)
10 Jun 2026TRIPP-FFX accepted for ESMO GI Rapid OralVisibility
12 Jun 2026Publication verifying localisation; Investor Hub launchedEvidence; IR
2 Jul 2026Selected for PALACROS / PULSELow-cost trial
3 Jul 2026Final HDE package filed with FDARegulatory
4 Jul 2026ESMO GI 2026 Rapid Oral (Munich)Visibility
13 Jul 2026Manufacturing validation completed (>50 doses)Margin pathway
20 Jul 2026Saudi SFDA approval; full reimbursement for nationalsMiddle East access
30 Jul 2026Q4 FY2026: cash A$6.5m; net operating outflow A$2.6mLiquidity
17 Aug 2026FDA HDE approval (dCCA)Landmark; US entry
28 Aug 2026FY2026 results: revenue +43.9%; loss −28.1% to A$10.86m; going-concern uncertainty retainedFinancial
7–10 Sep 2026A$5.6m from Pengana, Regal and Australian Ethical at a 9.9% premium; pro forma cash A$12.1mFunding; insider support
8 Sep 2026100th patient treated in SpainAdoption milestone
22 Oct 2026 (scheduled)Annual report date per InvestSMART calendar / Q1 FY2027 4C due by end of OctUpcoming
18 Nov 2026 (scheduled)AGM (virtual)Governance

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Total revenue and other income incl. RDTI and interest rose from AUD 1.1 Mn in FY2022 to AUD 5.2 Mn in FY2026.
OncoSil Medical Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Total revenue and other income incl. RDTI and interest1.11.51.61.65.2
Sales revenue0.20.40.51.21.7
Cost of sales11.6—2.32.4
Gross profit-0.7-1.2—-1.1-0.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.